NitroMist
NitroMist (NDA 021780), the FDA-approved nitroglycerin lingual aerosol for angina, is returning to market under Vicapsys Life Sciences: the product, its history, and the relaunch.
vicapsys.comCrawled Nov 19, 2026
NitroMist (NDA 021780), the FDA-approved nitroglycerin lingual aerosol for angina, is returning to market under Vicapsys Life Sciences: the product, its history, and the relaunch.
The Vicapsys platform: Stateline wholesale distribution, the federal and tribal channel, Puerto Rico brand supply at DACO pricing, NitroMist and VICAPSYN.
VICAPSYN: cell replacement for type 1 diabetes designed to work without systemic immunosuppression, using CXCL12 immune-isolation technology licensed from Massachusetts General Hospital.
Press release, October 5, 2026: Housekeeping starts with branding: Vicapsys Life Sciences adopts a new corporate identity by FutureBrand
Press releases and announcements from Vicapsys Life Sciences, Inc. (OTC: VICP).
Press release, November 2, 2026: Vicapsys Life Sciences provides shareholder update on VICAPSYN: program advancing toward Phase 1 human clinical trial, vertically integrated with the Company's Indian Health Service strategy
Press release, September 25, 2026: Vicapsys Life Sciences announces Advisory Board following completion of Stateline merger
Press release, September 22, 2026: Vicapsys Life Sciences completes reverse merger with Stateline Distributors of Puerto Rico and signs definitive agreement to acquire NitroMist
Contact Vicapsys Life Sciences, Inc. and Stateline Distributors of Puerto Rico: media and investor inquiries, business development, and the San Juan operations address.
Vicapsys Life Sciences, Inc. (OTC: VICP): a public pharmaceutical platform company combining licensed wholesale drug distribution, federal contracting access, and owned FDA-approved products.
Vicapsys Life Sciences announces its VICAPSYN™ program is progressing toward a Phase 1 human clinical trial. The development aligns with the company’s vertically integrated strategy under its Indian Health Service initiative, combining in-house capabilities with external partnerships.
Vicapsys Life Sciences unveils a rebranded corporate identity designed by FutureBrand. The update aligns with the company’s focus on life sciences innovation and market positioning. The redesign includes a refreshed logo, color scheme, and visual language to enhance brand recognition in the sector.
Vicapsys Life Sciences unveils an Advisory Board after finalizing its merger with Stateline. The move follows the integration of Stateline’s assets and operations into Vicapsys, expanding its capabilities in life sciences. The company now leverages combined expertise to advance its pipeline of medical technologies.
Vicapsys Life Sciences has completed a reverse merger with Stateline Distributors of Puerto Rico, integrating it as a wholly owned subsidiary. The company also signs a definitive agreement to acquire NitroMist, an FDA-approved nitroglycerin lingual aerosol product. This move creates a vertically integrated platform for pharmaceutical manufacturing and distribution, targeting federal, tribal, and underserved markets.
Vicapsys Life Sciences finalizes a reverse merger with Stateline Distributors of Puerto Rico. The company also signs a definitive agreement to acquire NitroMist®, a branded product line. The transaction positions Vicapsys to expand its distribution network and product portfolio in the life sciences sector.